Table 1.

Demographic characteristics of the participants, according to dose cohort and age group^a.

Cohort	Single-dose cohorts							Two-dose cohorts
	Age 21–55					Age 56–80		Age 21–55			Age 56–80
Variable	Cohort A 1 µg	Cohort B 5 µg	Cohort C 10 µg	Cohort D1 7.5 µg	Pooled placebo cohorts A–D1	Cohort D2 7.5 µg	Cohort D2 Placebo	Cohort E 5 µg	Cohort F 3 µg	Pooled placebo cohorts E–F	Cohort G 5 µg	Cohort H 3 µg	Pooled placebo cohorts G–H
Number of participants	5	10	5	5	10	5	2	12	12	8	12	12	8
Sex—n (%)
Male	3 (60)	6 (60)	2 (40)	4 (80)	8 (20)	5 (100)	1 (50)	8 (67)	10 (83)	5 (63)	11 (92)	8 (67)	7 (88)
Female	2 (40)	4 (40)	3 (60)	1 (20)	2 (20)	0 (0)	1 (50)	4 (33)	2 (17)	3 (38)	1 (8)	4 (33)	1 (13)
Race—n (%)b
Asian	5 (100)	10 (100)	5 (100)	4 (80)	10 (100)	5 (100)	2 (100)	11 (92)	10 (83)	7 (88)	12 (100)	12 (100)	7 (88)
White	0 (0)	0 (0)	0 (0)	1 (20)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	1 (13)	0 (0)	0 (0)	1 (13)
American Indian or Alaskan Native	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)
Hispanic Ethnic Group—n (%)b	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Age (years)c
Mean (SD)	35 (9.17)	39.5 (7.15)	41.4 (12.48)	40.4 (10.41)	33.5 (8.72)	64 (5.61)	61.5 (6.36)	34.5 (8.33)	38 (9.34)	39.1 (7.95)	62.3 (4.63)	61.7 (3.77)	63.3 (5.70)
Median [range]	32.0 [28–50]	40.0 [29–51]	44.0 [24–55]	47.0 [24–48]	34.5 [21–46]	64.0 [57–70]	61.5 [57–66]	35.5 [21–47]	35.0 [22–51]	37.0 [30–51]	62.0 [56–70]	61.5 [56–68]	64.5 [56–71]

N total number of subjects in each dose cohort, n number of subjects contributing to the summary, SD standard deviation.

^aPercentages may not total 100 because of rounding.

^bRace and ethnic group were reported by the participant.

^cThe age of the participants was the age at the time of screening.